Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL(TM) Trademark Approvals

Vivos Inc. (OTCQB: RDGL), a company focused on innovative cancer treatment technologies, recently announced key advancements in its intellectual property portfolio. On January 13, 2026, the United States Patent and Trademark Office (USPTO) granted Vivos U.S. Patent No. 12,521,452 B2, which secures its proprietary Precision Radionuclide Therapy™ (PRnT) platform. The patent encompasses a groundbreaking radioactive thermogel suspension that integrates biodegradable, thermosensitive PLGA-g-PEG hydrogel with yttrium-90 particles. This innovation allows targeted beta radiation delivery directly into solid tumors while minimizing damage to surrounding healthy tissue.

Vivos also celebrated the approval of its PRECISIONGEL™ trademark for publication in the U.S. and New Zealand, enhancing its brand identity in the marketplace. In addition, the company has filed a new patent application to further safeguard its PrecisionGel hydrogel technology. This application aims to broaden the use of the hydrogel for delivering a variety of therapeutic agents, such as anti-cancer agents and gene therapy, with an emphasis on timed release post-injection.

Dr. Mike Korenko, the CEO of Vivos Inc., emphasized that these developments solidify the company's intellectual property position, pivotal for driving shareholder value and fostering clinical advancements. Vivos aims to leverage its strengthened patent portfolio to explore global commercial expansion and strategic partnerships.

As a clinical-stage medical device firm, Vivos is developing RadioGel® for human applications and IsoPet® for veterinary use, both aiming to revolutionize oncology treatments. These strides in patent protection and trademark approvals are significant steps forward for the company's future growth and innovation in the cancer treatment sector. For more information on their products, visit www.VivosInc.com.

Vivos Inc. (OTCQB: RDGL) has recently achieved significant milestones with the issuance of a new U.S. patent and trademark approvals, enhancing its intellectual property position in the competitive cancer treatment landscape. The new patent for its Precision Radionuclide Therapy™ (PRnT) platform offers robust protection for its innovative RadioGel® and IsoPet® products. This technology, which allows for localized beta radiation delivery directly into tumors, presents a promising value proposition in oncological therapies.

From an investment perspective, several factors suggest that Vivos Inc. could be a strong candidate for potential growth. The company’s commitment to protecting its intellectual property through multiple patent filings not only solidifies its competitive edge but also positions it favorably for future strategic partnerships. As the healthcare market increasingly values innovation characterized by proprietary technologies, Vivos's advancements set it apart from competitors.

Moreover, the precision and efficacy promised by the PRnT platform could attract attention from both clinical partners and institutional investors. With the growing trend towards personalized medicine, Vivos’s focus on developing hydrogel-based delivery systems for anti-cancer agents addresses an unmet need for targeted treatment options.

However, investors should remain cognizant of inherent risks associated with clinical-stage companies, including regulatory challenges and the uncertain timelines often associated with drug development. Monitoring Vivos’s clinical progress and market response to its products will be critical in assessing potential returns.

In summary, while the recent achievements of Vivos Inc. bolster its market presence, potential investors should weigh these developments against the broader risks of investing in early-stage medical technology firms. An informed approach, recognizing both the company’s strengths and market uncertainties, will be vital for making sound investment decisions.